Feb 7th 2023 - Mar 21st 2023
Super excited for tomorrow's ER Guidance Call ... See more
They're FDA approved, have the best in class t... See more
Feb 8th 2023 - Mar 22nd 2023
$JSPR FDA approval here a few weeks ago, this baby isn’t going down,
positive PURSUIT outcome and FDA approval would op... See more
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.Feb 7th 2023 - Mar 21st 2023
A 300% gain in less than a month - and this time s... See more
$SLS my vote is get GPS green lighted for FDA appr... See more
Super excited for tomorrow's ER Guidance Call for our first ever FDA approved commercialized product, Briumvi!
They're FDA approved, have the best in class treatment, and is more affordable than the others.
$JAZZ $TGTX FDA APPROVED ON 12/28/22 . BUY/HOLD/ACCUMULATE
$KALA up 46%, rallies 3rd day in a row following FDA acceptance of IND application of KPI-012 & $TGTX is up 13% continued momentum following MS drug approvals.
Our best in class drug is FDA APPROVED.
$TGTX $KALA $HOTH $NUWE TGTX on fire 🔥 and solid from fundamentals perspective after yesterday FDA approval of Multiple Sclerosis Billion dollar drug revenue potential.
Great FDA approval news in a growing MS market with a need.
$TGTX , absolutely amazing….Scumbag’s Bank of America analyst rated TG today as underperform $6….total joke….I guess the analyst is waiting for FDA approval…LOL ….stick to loans and mortgages….very bullish TG community Longs….
$TGTX FDA approval for Billion dollar MS drug — great things in store 2023 $DRMA just officially dropped offering, makes me feel company has something good up it’s sleeve.
.. FDA APPROVED ON 12/28/22 BEST IN CLASS .
$JSPR FDA approval here a few weeks ago, this baby isn’t going down,
positive PURSUIT outcome and FDA approval would open a multibillion-dollar commercial opportunity for Viveve.
$BJDX .41 great entry ahead of FDA news just like $JSPR +600% monster run!
A 300% gain in less than a month - and this time sis has plenty of cash in the tank to keep on running to the FDA green light.
$SLS my vote is get GPS green lighted for FDA approval and ramp this company up for M&A. GPS and GFH009 are high potential assets
Really is a great set up here - Get the FDA Green light and collect $50M plus another $25M warrants at $5.40.
$SLS In addition to GPs FDA approval for AML secondary Remission patients - Gps + Keytruda/Checkpoint Inhibition is also best in class for Ovarian cancer patients.
- Gps FDA Approval only a matter of time and is worth $8B in Market Value to Big Pharma - SlS current market cap of $.067B Best Short term investment any of us will find for a long. time.
Great Set Up here - $25M total incoming in Q1/2, Then another $50M when Gps gets the FDA green light - usually that is when small bios need to raise cash, and shorts can cover -- Ange Has them Over a barrel.
I think the share price will be climbing all along the approach to the FDA green light.
2,500% to 5,000% Upside in this ahead of the Fda Green light for Gps, as the first immunotherapy to treat 20,000 AML remission patients.
His 25-year experience, with global drug/biologics approvals and Breakthrough Therapy Designation with FDA, will be of immense value to our organization, especially as 2023 will be a pivotal year for our Company - welcome Andrew!
